SCHEMBL493341

SCHEMBL493341

CNc1ccc(-c2nc3ccccc3s2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 10/20 1.00
GLA P06280 2/20 1.00
GAA P10253 2/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
TP53 P04637 1/20 0.67
MAPT P10636 4/20 0.66
SNCA P37840 1/20 0.66
SULT1A1 P50225 1/20 0.64
FLT4 P35916 2/20 0.64
INSR P06213 1/20 0.64
KDR P35968 1/20 0.64
AURKA O14965 1/20 0.64
RAB9A P51151 3/20 0.63
KDM4E B2RXH2 2/20 0.63
NPC1 O15118 2/20 0.63
ALDH1A1 P00352 1/20 0.63
LMNA P02545 1/20 0.63
MMP9 P14780 1/20 0.63
MMP8 P22894 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29523038 1.00 APP (1.00) APPGLAGAAMEN1KMT2A
SCHEMBL2628266 1.00 APP (1.00) APPGLAGAAMEN1KMT2A
SCHEMBL13853330 0.93 APP (1.00) APPGLAGAAMEN1KMT2A
SCHEMBL8397393 0.86 APP (0.76) APPGLAGAAMEN1KMT2A
SCHEMBL24155562 0.86 APP (0.76) APPGLAGAAMEN1KMT2A
SCHEMBL29474819 0.86 RAB9A (0.81) APPGLAGAAMEN1KMT2A
SCHEMBL366824 0.86 RAB9A (0.81) APPGLAGAAMEN1KMT2A
SCHEMBL24295138 0.84 RAB9A (0.79) APPGLAGAAMEN1KMT2A
SCHEMBL14195557 0.83 APP (0.71) APPGLAGAAMEN1KMT2A
SCHEMBL12472555 0.83 APP (0.71) APPGLAGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224727-A1 p53 amyloid-binding composition, method, and kit thereof INDIAN INSTITUTE OF TECHNOLOGY BOMBAY (IN) 2025-10-30 WO claimed
CN-120008222-A Overheat protection system is prevented in solar thermal-arrest field 西藏隆晟能源管理有限公司 2025-05-16 CN claimed
CN-116693933-A Method for degrading plastics 北京化工大学 2023-09-05 CN claimed
EP-2802871-B1 CHARACTERIZATION OF SUBVISIBLE PARTICLES USING A PARTICLE ANALYZER TAKEDA PHARMACEUTICALS CO (JP) 2022-07-27 EP claimed
EP-2435844-A1 SYSTEMS, DEVICES, METHODS, AND COMPOSITIONS INCLUDING FERROMAGNETIC STRUCTURES Searete LLC (US) 2012-04-04 EP claimed
US-20100303731-A1 Systems, devices, methods, and compositions including selectively accessible ferromagnetic structures SEARETE LLC 2010-12-02 US claimed
WO-2010138202-A1 SYSTEMS, DEVICES, METHODS, AND COMPOSITIONS INCLUDING FERROMAGNETIC STRUCTURES SEARETE, LLC (US) 2010-12-02 WO claimed
US-20080085238-A1 Small Molecules for Imaging Protein-Protein Interactions The Government of the United States of America as represented (US) 2008-04-10 US claimed
EP-3129065-B1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS AKAMARA THERAPEUTICS INC (US) 2026-05-13 EP disclosed
CN-122010854-A Compound for preparing photoresist film, photosensitive resin composition and photosensitive laminate 珦盛新材料(珠海)有限公司 2026-05-12 CN disclosed
EP-4724816-A2 METHODS FOR DETECTING THE PRESENCE OF AT LEAST ONE MISFOLDED FORM OF SOD1 IN A BIOLOGICAL SAMPLE Mclaughlin Research Institute for Biomedical Sciences (US) 2026-04-15 EP disclosed
US-20260022227-A1 METHOD FOR DEGRADING AND DECOMPOSING PLASTIC USING ENZYMES EXPRESSED BY LEPIDOPTERA THE AMERICAN UNIVERSITY IN CAIRO (EG) 2026-01-22 US disclosed
US-12493244-B2 Photosensitive resin composition, photosensitive dry film, and pattern formation method SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-12-09 US disclosed
US-20250340547-A1 NOVEL COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN THE BRAIN NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) 2025-11-06 US disclosed
CN-1535268-A Thioflavin derivatives for antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposits ƥ�ȱ���ѧ 2004-10-06 CN disclosed
WO-2004083195-A1 BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES UNIVERSITY OF PITTSBURGH (US) 2004-09-30 WO disclosed
US-20030236391-A1 Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy UNIVERSITY OF PITTSBURGH 2003-12-25 US disclosed
EP-1334091-A2 THIOFLAVIN DERIVATIVES AND THEIR USE IN DIAGNOSIS AND THERAPY OF ALZHEIMER'S DISEASE UNIVERSITY OF PITTSBURGH (US) 2003-08-13 EP disclosed
US-20020133019-A1 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition PITTSBURGH, UNIVERSITY OF 2002-09-19 US disclosed
WO-2002016333-A2 THIOFLAVIN DERIVATIVES AND THEIR USE IN DIAGNOSIS AND THERAPHY OF ALZHEIMER'S DISEASE UNIVERSITY OF PITTSBURGH (US) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085238-A1 Small Molecules for Imaging Protein-Protein Interactions HSPBP1, HSPA2, HSPA8 APP 36/4885GLA 1510/4885GAA 1890/4885
US-20260022227-A1 METHOD FOR DEGRADING AND DECOMPOSING PLASTIC USING ENZYMES EXPRESSED BY LEPIDOPTERA CMBL, LCT, LIPE APP 2917/4885GLA 1071/4885GAA 235/4885
US-20020133019-A1 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition APP, PSEN2, MAPT APP 1/4885GLA 148/4885GAA 1121/4885
US-20250340547-A1 NOVEL COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN THE BRAIN MAPT, FABP7, HTT APP 21/4885GLA 1727/4885GAA 4005/4885
US-20030236391-A1 Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy TTR, APP, BACE1 APP 2/4885GLA 133/4885GAA 1121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.